Generated: May 23, 2017
|Title:||Controlled release formulation of divalproex sodium|
|Abstract:||A controlled release tablet formulation which permits once daily dosing in the treatment of epilepsy comprises from about 50 weight percent to about 55 weight percent of an active ingredient selected from the group consisting of valproic acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, and valpromide; from about 20 weight percent to about 40 weight percent hydroxypropyl methylcellulose; from about 5 weight percent to about 15 weight percent lactose, from about 4 weight percent to about 6 weight percent microcrystalline cellulose, and from about 1 weight percent to about 5 weight percent silicon dioxide having an average particle size ranging between about 1 micron and about 10 microns; all weight percentages based upon the total weight of the tablet dosage form. Also disclosed are pre-tableting granular formulations, methods of making the granular formulations and tablets, and a method of treating epilepsy employing the controlled release tablet formulations of the invention.|
|Inventor(s):||Qiu; Yihong (Gurnee, IL), Poska; Paul Richard (Mundelein, IL), Cheskin; Howard S. (Glencoe, IL), Bollinger; J. Daniel (Libertyville, IL), Engh; Robert K. (Kenosha, WI)|
|Assignee:||Abbott Laboratories (Abbott Park, IL)|
1. A method of treating epilepsy comprising administering once daily to a patient in need of such treatment a controlled release tablet dosage form comprising a daily therapeutic dose
of divalproex sodium from about 50 to 55 weight percent in a hydrophilic matrix comprising: a) from about 20 weight percent to about 40 weight percent hydroxypropyl methylcellulose; b) from about 5 weight percent to about 15 weight percent lactose; c)
from about 4 weight percent to about 6 weight percent microcrystalline cellulose; and d) from about 1 to about 5 weight percent silicon dioxide having an average particle size ranging between about 1 micron and about 10 microns; all weight percentages
based upon the total weight of the tablet dosage form.
2. The method of claim 1 wherein said silicon dioxide has an average particle size
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.